Biotechnology
Orizuru Therapeutics seeks breakthrough to reduce insulin doses for Type 1 patients
Orizuru Therapeutics looks to process pancreatic islet cells created from iPS cells into sheets and transplant them into patients with Type 1 diabetes. (Orizuru Therapeutics)
NORIYUKI TAKADA, HINAKO BANNO and TAITO KUROSE
TOKYO — Japanese biotech startup Orizuru Therapeutics will start clinical trials as soon as fiscal 2027 for a diabetes treatment using induced pluripotent (iPS) stem cells that could reduce insulin doses needed to lower blood sugar levels, potentially transforming the way the disease is treated.
